Effect of remifentanil during cardiopulmonary bypass on incidence of acute kidney injury after cardiac surgery.

Effect of remifentanil during cardiopulmonary bypass on incidence of acute kidney injury after cardiac surgery.

Click the title to purchase the article.

Background:

"Acute kidney injury (AKI) after cardiopulmonary bypass (CPB) is a well-known postoperative complication. Remifentanil, which is a commonly used ultra-short-acting opioid, has antiinflammatory and sympatholytic effects with improvement of microcirculation."1


1. Effect of remifentanil during cardiopulmonary bypass on incidence of acute kidney injury after cardiac surgery.
Sakai W, Yoshikawa Y, Hirata N, Yamakage M.
J Anesth. 2017 Oct 30. [Epub ahead of print]

 

Recent Stories
International quality improvement initiatives

Cerebral strokes in children on intracorporeal ventricular assist devices: analysis of the EUROMACS Registry.

Does acute kidney injury affect survival in adults with acute respiratory distress syndrome requiring extracorporeal membrane oxygenation?

AmSECT Membership Eligibility

An Active Member shall be any perfusionist active in the practice of extracorporeal circulation technology. There are also opportunities to become a Transitional Active Member for those less than a year removed from graduation from an approved accredited training program. Other options include; an Associate Membership, International Membership, Perioperative Blood Management Clinician Membership, and Student Membership.

Click Here to Learn More

Looking for Employment Opportunities?

AmSECT members may post an available position for a perfusion specialty at your institution or firm.

Non-members may also post positions free of charge, to be reviewed by National Headquarters prior to posting.

Members - Click to Post a Position
Non-Members - Click to Post a Position

Contact AmSECT


AmSECT National Headquarters
330 N Wabash Ave, Suite 2000
Chicago, IL 60611

  Phone: (312) 321-5156
  Fax: (312) 673-6656
  Email: amsect@amsect.org

AmSECT © 2018 | View Privacy Policy | Site Map